Related Experiment Video
Updated: Apr 10, 2026
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report
Valeriy Parfenov1, Renaud Du Pasquier, Myriam Schluep
1Department of Neurology, Division of Neuroimmunology, University Hospital of Lausanne, Lausanne, Switzerland.
Introduction:
Malignant variant is a rare subtype of multiple sclerosis (MS) that is rapidly progressive and may lead to significant disability or even death. No consensus exists on best management of this disorder, although corticosteroids and plasmapheresis are commonly used in the acute phase, followed either by MS-specific disease-modifying therapy or an immunosuppressant.
Case Report:
The patient is a 30-year-old man with relapsing-remitting MS previously well controlled with natalizumab, who has developed fulminant disease activity upon natalizumab cessation. In the acute phase, patient had a suboptimal response to multiple corticosteroid treatments but responded very well to plasmapheresis. Patient continued to have worsening disease activity despite fingolimod treatment. Disease control has been eventually achieved by switching to rituximab.
Conclusion:
Rituximab treatment should be considered for a patient with fulminant MS who responded well to plasmapheresis.
Insights
Malignant multiple sclerosis (MS) is a rare, aggressive form of the disease. Rituximab may be an effective treatment option for patients with fulminant MS who respond well to plasmapheresis.
Area of Science:
- Neuroimmunology
- Neurology
- Clinical Medicine
Background:
- Malignant multiple sclerosis (MS) presents as a rapidly progressive subtype.
- Optimal management strategies for malignant MS remain undefined.
- Current acute-phase treatments include corticosteroids and plasmapheresis, followed by disease-modifying therapies or immunosuppressants.
Observation:
- A 30-year-old male with relapsing-remitting MS experienced fulminant disease activity after discontinuing natalizumab.
- Initial corticosteroid treatments were suboptimal, but plasmapheresis yielded a positive response.
- Despite fingolimod treatment, disease activity persisted.
Findings:
- Switching to rituximab eventually achieved disease control in this patient.
- This case highlights a potential therapeutic option for severe MS.
- Plasmapheresis was effective in the acute phase, preceding rituximab initiation.
Implications:
- Rituximab should be considered for managing fulminant multiple sclerosis.
- This case underscores the need for tailored treatment approaches in aggressive MS.
- Further research into rituximab's efficacy in malignant MS is warranted.
